Surfactant can be supplemented before the neonate needs it

Area of Science:

• Neonatal Medicine
• Pulmonary Physiology
• Biochemistry

Background:

• Pulmonary surfactant, primarily dipalmitoylphosphatidylcholine (DPPC), is crucial for lung function.
• Respiratory distress syndrome (RDS) in premature infants results from a deficiency in pulmonary surfactant.
• Early attempts to treat RDS using only DPPC were unsuccessful due to its slow adsorption rate.

Purpose of the Study:

• To evaluate the efficacy of natural surfactant supplementation in preventing RDS in high-risk neonates.
• To compare the outcomes of infants receiving surfactant before the first breath versus a control group.

Main Methods:

• A randomized clinical trial was conducted involving infants at high risk for RDS.
• Infants received a surfactant preparation derived from calf lung lavage lipids prior to their first breath.
• A control group received standard care without surfactant supplementation.

Main Results:

• The group receiving surfactant supplementation showed a significantly lower neonatal mortality rate (1 death out of 39) compared to the control group (6 deaths out of 33).
• Natural surfactant demonstrated rapid adsorption and film formation at the air-liquid interface, unlike DPPC alone.
• Surfactant supplementation facilitated lung aeration and stability in neonates.

Conclusions:

• Natural surfactant supplementation is an effective treatment for high-risk infants developing RDS.
• Prompt administration of natural surfactant before the first breath enhances neonatal lung maturity and survival.
• The composition and rapid adsorption properties of natural surfactant are critical for its therapeutic effect in RDS.